Mabvax Therapeutics (MBVX) 8-K/A Changes in Registrant's Certifying Accountant

Exhibit 16.1

November 12, 2013

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Ladies and Gentlemen:

We have read Item 4.01(a) of Form 8-K/A dated November 12, 2013, of Telik, Inc. and are in agreement with the statements contained in the first, second, third and fourth paragraphs on page 2 therein. We have no basis to agree or disagree with other statements of the registrant contained therein.

/s/ Ernst & Young LLP